{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:25Z","timestamp":1791067045638,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11523-024-01063-y","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:48:10Z","timestamp":1714574890000},"page":"575-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX\/CAPOX Therapy: A Japanese Claims Database Study"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-4507","authenticated-orcid":false,"given":"Yoshinori","family":"Kagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-1497","authenticated-orcid":false,"given":"Chaochen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-3041","authenticated-orcid":false,"given":"Yongzhe","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-2483","authenticated-orcid":false,"given":"Yoshinori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-197X","authenticated-orcid":false,"given":"Zhihong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"1063_CR1","unstructured":"International Agency for Research on Cancer. Colorectal cancer. World Health Organization; 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/10_8_9-Colorectum-fact-sheet.pdf. Accessed 16 Apr 2024."},{"key":"1063_CR2","unstructured":"International Agency for Research on Cancer. Japan fact sheet. The Global Cancer Observatory; 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/392-japan-fact-sheets.pdf. Accessed 16 Apr 2024."},{"key":"1063_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14: 101174.","journal-title":"Transl Oncol"},{"key":"1063_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1\u201342.","journal-title":"Int J Clin Oncol"},{"key":"1063_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00535-021-01771-6","volume":"56","author":"Y Ahiko","year":"2021","unstructured":"Ahiko Y, Shida D, Kudose Y, Nakamura Y, Moritani K, Yamauchi S, et al. Recurrence hazard of rectal cancer compared with colon cancer by adjuvant chemotherapy status: a nationwide study in Japan. J Gastroenterol. 2021;56:371\u201381.","journal-title":"J Gastroenterol"},{"key":"1063_CR6","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Colon cancer. National Comprehensive Cancer Network; 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 16 Apr 2024."},{"key":"1063_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","journal-title":"Lancet Oncol"},{"key":"1063_CR8","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/annonc\/mdv197","volume":"26","author":"S Iwamoto","year":"2015","unstructured":"Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol. 2015;26:1427\u201333.","journal-title":"Ann Oncol"},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499\u2013508.","journal-title":"Lancet Oncol"},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"1063_CR11","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706\u201313.","journal-title":"J Clin Oncol"},{"key":"1063_CR12","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/cas.13098","volume":"107","author":"K Shitara","year":"2016","unstructured":"Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, et al. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci. 2016;107:1843\u201350.","journal-title":"Cancer Sci"},{"key":"1063_CR13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O\u2019Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539\u201344.","journal-title":"J Clin Oncol"},{"key":"1063_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","volume":"50","author":"J Tabernero","year":"2014","unstructured":"Tabernero J, Van Cutsem E, Lakomy R, Prausova J, Ruff P, van Hazel GA, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50:320\u201331.","journal-title":"Eur J Cancer"},{"key":"1063_CR15","unstructured":"Medical database overview (as of the end of March 2023). Number of actual patients: 43.22 million [Japanese]. Medical Data Vision; 2023. https:\/\/www.mdv.co.jp\/press\/2023\/detail_1979.html. Accessed 16 Apr 2024."},{"key":"1063_CR16","unstructured":"Cancer Statistics in Japan: 2023. Foundation for promotion of cancer research; 2023. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2023.pdf. Accessed 16 Apr 2024."},{"key":"1063_CR17","unstructured":"Ethical guidelines for medical and health research involving human subjects. Tokyo: Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare; 2018. https:\/\/www.lifescience.mext.go.jp\/files\/pdf\/n2181_01.pdf. Accessed 16 Apr 2024."},{"key":"1063_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.946850","volume":"12","author":"C Cremolini","year":"2022","unstructured":"Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2022;12: 946850.","journal-title":"Front Oncol"},{"key":"1063_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing, 3.2.1 edn. Vienna: R Foundation for Statistical Computing; 2021."},{"key":"1063_CR20","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1016\/j.annonc.2022.04.166","volume":"33","author":"N Sugimoto","year":"2022","unstructured":"Sugimoto N, Nakata K, Miyo M, Yoshioka S, Kagawa Y, Naito A, et al. P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin\/fluoropyrimidine (RAINCLOUD). Ann Oncol. 2022;33:S274.","journal-title":"Ann Oncol"},{"key":"1063_CR21","first-page":"1967","volume":"34","author":"S Iwamoto","year":"2014","unstructured":"Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C, et al. Multicenter phase II study of second-line cetuximab plus folinic acid\/5-fluorouracil\/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res. 2014;34:1967\u201373.","journal-title":"Anticancer Res"},{"key":"1063_CR22","doi-asserted-by":"publisher","first-page":"10426","DOI":"10.1038\/s41598-017-11048-9","volume":"7","author":"A Passardi","year":"2017","unstructured":"Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, et al. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep. 2017;7:10426.","journal-title":"Sci Rep"},{"key":"1063_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/annonc\/mdt523","volume":"25","author":"M Peeters","year":"2014","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Final results from a randomized phase 3 study of FOLFIRI \u00b1 panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25:107\u201316.","journal-title":"Ann Oncol"},{"key":"1063_CR24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853\u201360.","journal-title":"Lancet Oncol"},{"key":"1063_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329:1271\u201382.","journal-title":"JAMA"},{"key":"1063_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246160","volume":"16","author":"E Shinozaki","year":"2021","unstructured":"Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, et al. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: a retrospective observational study using an administrative database. PLoS ONE. 2021;16: e0246160.","journal-title":"PLoS ONE"},{"key":"1063_CR27","doi-asserted-by":"publisher","first-page":"2176056","DOI":"10.1155\/2018\/2176056","volume":"2018","author":"Y Itatani","year":"2018","unstructured":"Itatani Y, Kawada K, Sakai Y. Treatment of elderly patients with colorectal cancer. Biomed Res Int. 2018;2018:2176056.","journal-title":"Biomed Res Int"},{"key":"1063_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4251\/wjgo.v7.i10.204","volume":"7","author":"M Millan","year":"2015","unstructured":"Millan M, Merino S, Caro A, Feliu F, Escuder J, Francesch T. Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol. 2015;7:204\u201320.","journal-title":"World J Gastrointest Oncol."},{"key":"1063_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.clcc.2015.10.003","volume":"15","author":"J McLean","year":"2016","unstructured":"McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15:135\u201340.","journal-title":"Clin Colorectal Cancer"},{"key":"1063_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12885-020-6557-5","volume":"20","author":"R Xu","year":"2020","unstructured":"Xu R, Wang W, Zhu B, Lin X, Ma D, Zhu L, et al. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. BMC Cancer. 2020;20:131.","journal-title":"BMC Cancer"},{"key":"1063_CR31","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1007\/s12325-022-02122-4","volume":"39","author":"H Satake","year":"2022","unstructured":"Satake H, Kagawa Y, Shinozaki E, Tanizawa Y, Jin L, Cai Z, et al. Real-world data analysis of second-line antiangiogenic targeted treatments following anti-epidermal growth factor receptor monoclonal antibodies and first-line FOLFOX for patients with metastatic colorectal cancer. Adv Ther. 2022;39:2596\u2013613.","journal-title":"Adv Ther"},{"key":"1063_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40801-015-0059-9","volume":"3","author":"RC Parikh","year":"2016","unstructured":"Parikh RC, Du XL, Morgan RO, Lairson DR. Patterns of treatment sequences in chemotherapy and targeted biologics for metastatic colorectal cancer: findings from a large community-based cohort of elderly patients. Drugs Real World Outcomes. 2016;3:69\u201382.","journal-title":"Drugs Real World Outcomes"},{"key":"1063_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mds289","volume":"24","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2013;24:186\u201392.","journal-title":"Ann Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01063-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:10:49Z","timestamp":1720458649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01063-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01063-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"5 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly Japan K.K. Leo J. Philip Tharappel of Eli Lilly Services India Private Limited, Bengaluru, India provided medical writing and editorial support, which was funded by Eli Lilly Japan K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yoshinori Kagawa received honoraria from Bayer, Chugai, Eli Lilly Japan K.K., Merck, MSD, Ono, Sanofi, Taiho, Takeda, and Yakult. Chaochen Wang, Yongzhe Piao, Long Jin, Yoshinori Tanizawa, and Zhihong Cai are employees of Eli Lilly Japan K.K. and may hold stock and\/or stock options in the company. Yu Sunakawa or his institution received grants or contracts from Chugai, Eli Lilly Japan K.K., Ohtsuka Pharmaceutical, Sanofi, Taiho, and Takeda. He received payments or honoraria from Bayer, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eli Lilly Japan K.K., Guardant Health, Merck Biopharma, MSD, Ono, Sysmex, Taiho, and Takeda. He also participated on an advisory board for Guardant Health, Merck Biopharma, and Ono.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with ethical principles originating from the Declaration of Helsinki and that were consistent with Good Pharmacoepidemiology Practices. This study used retrospective de-identified data so an ethical review and informed consent were not required, consistent with the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available at Eli Lilly Japan K.K on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design: CW, LJ, YK, YS. Collection and assembly of data: data analysis and\/or interpretation: YK, CW, YP, LJ, YT, ZC, YS. Manuscript writing: YK, YS. Final approval of manuscript: YK, CW, YP, LJ, YT, ZC, YS. Accountable for all aspects of the work: YK, CW, YP, LJ, YT, ZC, YS.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}